Stockreport

IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer

AstraZeneca PLC Ordinary Shares  (AZN) 
Last astrazeneca plc ordinary shares earnings: 2/5 04:00 pm Check Earnings Report
US:NYSE Investor Relations: astrazeneca.com/investor-relations.html
PDF IMFINZI plus IMJUDO combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embo [Read more]